CD247 and neoplasm: CAR-T cell therapy was first tested in ovarian cancer [17], where administration of T cells engineered to express an anti-αFR CAR composed of the murine MOv18 scFv and a CD3z endodomain was shown to be feasible but did not induce tumor regression due to the poor persistence of the gene-modified T cells.